Glucovance: Advanced Dual-Therapy for Effective Type 2 Diabetes Management
| Product dosage: 2.5mg/400mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.61 | $48.19 (0%) | 🛒 Add to cart |
| 60 | $1.36 | $96.38 $81.32 (16%) | 🛒 Add to cart |
| 90 | $1.24 | $144.58 $111.44 (23%) | 🛒 Add to cart |
| 120 | $1.16 | $192.77 $139.56 (28%) | 🛒 Add to cart |
| 180 | $1.08 | $289.15 $194.78 (33%) | 🛒 Add to cart |
| 270 | $1.00 | $433.73 $271.08 (38%) | 🛒 Add to cart |
| 360 | $0.80
Best per pill | $578.31 $289.15 (50%) | 🛒 Add to cart |
| Product dosage: 5mg/500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.71 | $51.20 (0%) | 🛒 Add to cart |
| 60 | $1.51 | $102.41 $90.36 (12%) | 🛒 Add to cart |
| 90 | $1.41 | $153.61 $126.50 (18%) | 🛒 Add to cart |
| 120 | $1.34 | $204.82 $160.64 (22%) | 🛒 Add to cart |
| 180 | $1.27 | $307.23 $228.91 (25%) | 🛒 Add to cart |
| 270 | $1.20 | $460.84 $325.30 (29%) | 🛒 Add to cart |
| 360 | $0.95
Best per pill | $614.45 $343.37 (44%) | 🛒 Add to cart |
Glucovance combines two proven antihyperglycemic agents, glyburide and metformin, into a single tablet to provide synergistic control of blood glucose levels. This fixed-dose combination is specifically indicated for the management of type 2 diabetes mellitus in adults when diet and exercise alone do not provide adequate glycemic control. It leverages complementary mechanisms of action to address both insulin resistance and insulin secretion deficiencies, offering a comprehensive approach to diabetes management. Clinical studies demonstrate its efficacy in reducing HbA1c levels more effectively than monotherapy with either component alone.
Features
- Contains glyburide (a sulfonylurea) and metformin hydrochloride (a biguanide) in a single oral formulation
- Available in multiple strength combinations: 1.25 mg/250 mg, 2.5 mg/500 mg, and 5 mg/500 mg
- Dual mechanism of action targeting both pancreatic beta-cell insulin secretion and peripheral insulin sensitivity
- Film-coated tablets designed for once or twice daily administration
- Manufactured under strict pharmaceutical quality control standards
- Requires prescription and regular glucose monitoring during therapy
Benefits
- Provides superior glycemic control compared to monotherapy regimens
- Reduces hemoglobin A1c levels effectively through complementary mechanisms
- May allow for lower doses of individual components, potentially minimizing side effects
- Offers convenience of combination therapy in a single tablet, improving adherence
- Addresses both insulin resistance and impaired insulin secretion
- May help delay disease progression and reduce diabetes-related complications
Common use
Glucovance is primarily prescribed for adults with type 2 diabetes mellitus who have not achieved adequate glycemic control with diet and exercise alone. It is typically used when monotherapy with either metformin or a sulfonylurea has proven insufficient. The medication is often initiated in patients with HbA1c levels above target despite lifestyle modifications and single-agent therapy. Healthcare providers may consider Glucovance for patients who would benefit from the convenience of a combination product to simplify their medication regimen and improve adherence.
Dosage and direction
The dosage of Glucovance must be individualized based on the patient’s current regimen, effectiveness, and tolerance. The usual starting dose is 1.25 mg/250 mg once or twice daily with meals. Dose titration should be gradual, with increments no more frequently than every two weeks, based on blood glucose response. The maximum recommended daily dose is 20 mg glyburide/2000 mg metformin. Administration should always occur with meals to reduce gastrointestinal side effects. Renal function must be assessed before initiation and regularly during treatment. Elderly patients should receive conservative initial dosing with careful monitoring.
Precautions
Regular monitoring of blood glucose and HbA1c is essential during therapy. Renal function should be assessed before initiation and at least annually thereafter, with more frequent monitoring in patients at risk of renal impairment. Temporary discontinuation may be necessary before radiographic procedures involving intravascular iodinated contrast materials. Patients should be advised regarding the recognition and management of hypoglycemia. Lactic acidosis, while rare, represents a serious metabolic complication that requires immediate medical attention if suspected. Hepatic impairment may affect drug metabolism and necessitate dose adjustment. Vitamin B12 levels should be monitored periodically with long-term use.
Contraindications
Glucovance is contraindicated in patients with renal disease or renal dysfunction (serum creatinine levels ≥1.5 mg/dL in males, ≥1.4 mg/dL in females). Contraindications include known hypersensitivity to glyburide, metformin, or other sulfonylureas. It must not be used during metabolic acidosis, including diabetic ketoacidosis. The medication is contraindicated in patients with acute or chronic disease which may cause tissue hypoxia, such as cardiac or respiratory failure, recent myocardial infarction, or septicemia. Use is prohibited in patients with history of lactic acidosis. The medication is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.
Possible side effects
Common adverse reactions include gastrointestinal symptoms: diarrhea, nausea, vomiting, abdominal discomfort, and flatulence (occurring in >5% of patients). Hypoglycemia may occur, particularly with inadequate caloric intake, excessive alcohol consumption, or concomitant use of other glucose-lowering agents. Other reported side effects include headache, dizziness, and taste disturbance. Rare but serious adverse effects include lactic acidosis, hemolytic anemia, hepatic porphyria, and photosensitivity reactions. Sulfonylurea components have been associated with disulfiram-like reactions with alcohol consumption. Metformin may cause decreased vitamin B12 absorption with prolonged use.
Drug interaction
Concomitant use with other hypoglycemic agents may increase the risk of hypoglycemia. Drugs that may potentiate the hypoglycemic effect include: insulin, other oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, propoxyphene, salicylates, sulfonamide antibiotics, and warfarin. Drugs that may reduce hypoglycemic effect include: corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. Beta-blockers may mask symptoms of hypoglycemia. Alcohol potentiates the effect of metformin on lactate metabolism and may increase the risk of lactic acidosis.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistent timing of administration with meals is important for maintaining stable blood glucose levels. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming therapy, as dose adjustment may be necessary.
Overdose
Overdose of Glucovance may produce hypoglycemia, which should be treated appropriately with glucose administration, monitoring, and supportive measures. Severe hypoglycemic reactions requiring hospitalization may occur. Metformin overdose may result in lactic acidosis, characterized by elevated blood lactate levels, decreased blood pH, electrolyte disturbances, and hypothermia. Lactic acidosis constitutes a medical emergency requiring immediate hospitalization. Hemodialysis may be effective for removing both metformin and glyburide, correcting acidosis, and removing accumulated lactate. Treatment should be symptomatic and supportive, with continuous monitoring of vital signs, blood glucose, and electrolyte levels.
Storage
Store at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep container tightly closed and protect from moisture. Dispense in original container with desiccant canister. Keep out of reach of children and pets. Do not use if the blister pack or bottle seal is broken or missing. Do not transfer to other containers, as moisture protection may be compromised. Properly discard any unused medication after the expiration date printed on the packaging.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Glucovance is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to therapy may vary, and treatment decisions should be based on professional medical judgment considering the patient’s complete medical history and current condition. Patients should not adjust their dosage or discontinue medication without consulting their healthcare provider. The manufacturer and distributors are not liable for any consequences arising from the use or misuse of this information.
Reviews
Clinical studies demonstrate that Glucovance provides effective glycemic control in patients with type 2 diabetes. In a 24-week randomized trial, patients receiving Glucovance achieved significantly greater reductions in HbA1c compared to monotherapy with either component alone. The combination therapy was generally well-tolerated, with gastrointestinal symptoms being the most commonly reported adverse events. Many healthcare providers appreciate the convenience of the fixed-dose combination for improving patient adherence. Some studies suggest that the combination may allow for lower doses of individual components, potentially reducing side effects while maintaining efficacy. Long-term data support its role in comprehensive diabetes management strategies.